A recent development in Singapore on January 20, 2026, revealed that HistoIndex, an innovative company specializing in AI-powered digital pathology solutions for chronic liver disease, has forged a key partnership with the esteemed Houston Research Institute (HRI). This collaboration is significant as HRI is renowned for its expertise in executing clinical trials, enhancing the potential for groundbreaking advancements in the field. This marks a pivotal moment in the realm of liver disease research, leveraging cutting-edge technology and research capabilities.